The DOI matches its Crossref record; 262 of the 262 references it cites were found in a registry or an index.
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer
Open accessAbstract
The reciprocal interplay of cancer cells and host cells is an indispensable prerequisite for tumor growth and progression. Cells of both the innate and adaptive immune system, in particular tumor-associated macrophages (TAMs) and T cells, as well as cancer-associated fibroblasts enter into a malicious liaison with tumor cells to create a tumor-promoting and immunosuppressive tumor microenvironment (TME). Ovarian cancer, the most lethal of all gynecological malignancies, is characterized by a unique TME that enables specific and efficient metastatic routes, impairs immune surveillance, and mediates therapy resistance. A characteristic feature of the ovarian cancer TME is the role of resident host cells, in particular activated mesothelial cells, which line the peritoneal cavity in huge numbers, as well as adipocytes of the omentum, the preferred site of metastatic lesions. Another crucial factor is the peritoneal fluid, which enables the transcoelomic spread of tumor cells to other pelvic and peritoneal organs, and occurs at more advanced stages as a malignancy-associated effusion. This ascites is rich in tumor-promoting soluble factors, extracellular vesicles and detached cancer cells as well as large numbers of T cells, TAMs, and other host cells, which cooperate with resident host cells to support tumor progression and immune evasion. In this review, we summarize and discuss our current knowledge of the cellular and molecular interactions that govern this interplay with a focus on signaling networks formed by cytokines, lipids, and extracellular vesicles; the pathophysiologial roles of TAMs and T cells; the mechanism of transcoelomic metastasis; and the cell type selective processing of signals from the TME.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–262 of 262
IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages
Smallie, T., Ricchetti, G., Horwood, N. J., Feldmann, M., Clark, A. R., & Williams, L. M. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20100414 · Cited by 115
Regulation of Invasion of Epithelial Ovarian Cancer by Transforming Growth Factor-β
Rodriguez, G. C., Haisley, C., Hurteau, J. A., Moser, T. L., Whitaker, R. S., Bast, R. C., & Stack, M. S. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2000.6042 · Cited by 114
Reinartz, S., Finkernagel, F., Adhikary, T., Rohnalter, V., Schumann, T., Schober, Y., Nockher, W. A., Nist, A., Stiewe, T., Jansen, J. M., et al. (2016) · Genome biology · doi:10.1186/s13059-016-0956-6 · Cited by 113
Self-citationTymoszuk, P., Evens, H., Marzola, V., Wachowicz, K., Wasmer, M.-H., Datta, S., Müller‐Holzner, E., Fiegl, H., Böck, G., van Rooijen, N., et al. (2014) · European Journal of Immunology · doi:10.1002/eji.201344304 · Cited by 111
Martins, F. C., de Santiago, I., Trinh, A. C., Xian, J., Guo, A., Sayal, K., Jimenez‐Liñan, M., Deen, S., Driver, K. E., Mack, M. L., et al. (2014) · Genome biology · doi:10.1186/s13059-014-0526-8 · Cited by 108
Bellora, F., Castriconi, R., Dondero, A., Pessino, A. M., Nencioni, A., Liggieri, G., Moretta, L., Mantovani, A., Moretta, A., & Bottino, C. (2014) · European Journal of Immunology · doi:10.1002/eji.201344130 · Cited by 104
Schumann, T., Adhikary, T., Wortmann, A., Finkernagel, F., Lieber, S., Schnitzer, E., Legrand, N., Schober, Y., Nockher, W. A., Toth, P. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3826 · Cited by 102
Self-citationAN ELECTRON MICROSCOPIC STUDY OF THE INVASION OF ASCITES TUMOR CELLS INTO THE ABDOMINAL WALL.
Birbeck, M. S. C., & Wheatley, D. N. (1965) · PubMed · Cited by 102
Bhushan, S., Tchatalbachev, S., Lu, Y., Fröhlich, S., Fijak, M., Vijayan, V., Chakraborty, T., & Meinhardt, A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401132 · Cited by 102
Landskron, J., Helland, Ø., Torgersen, K. M., Aandahl, E. M., Gjertsen, B. T., Bjørge, L., & Taskén, K. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1636-6 · Cited by 102
Wang, Y., Li, L., Guo, X., Jin, X., Sun, W., Zhang, X., & Xu, R. C. (2012) · Cytokine · doi:10.1016/j.cyto.2012.04.020 · Cited by 102
Kusuda, T., Shigemasa, K., Arihiro, K., Fujii, T., Nagai, N., & Ohama, K. (2005) · Oncology Reports · doi:10.3892/or.13.6.1153 · Cited by 101
NF-κB as a target for cancer therapy
Melisi, D., & Chiao, P. J. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.2.133 · Cited by 99
Finkernagel, F., Reinartz, S., Lieber, S., Adhikary, T., Wortmann, A., Hoffmann, N., Bieringer, T., Nist, A., Stiewe, T., Jansen, J. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12180 · Cited by 99
Self-citationParadoxical effects of tumour necrosis factor in experimental ovarian cancer
Malik, S., Griffin, D., Fiers, W. C., & Balkwill, F. R. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910440529 · Cited by 97
Bamias, A., Koutsoukou, V., Terpos, E., Tsiatas, M. L., Liakos, C., Tsitsilonis, O., Rodolakis, A., Voulgaris, Z., Vlachos, G. D., Papageorgiou, T., et al. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.10.018 · Cited by 97
β2-Adrenoreceptor Agonist Inhibits Antigen Cross-Presentation by Dendritic Cells
Hervé, J., Dubreil, L., Tardif, V., Terme, M., Pogu, S., Anegón, I., Rozec, B. R., Gauthier, C., Bach, J., & Blancou, P. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201391 · Cited by 96
Tanyi, J. L., Hasegawa, Y., LaPushin, R., Morris, A. J., Wolf, J. K., Berchuck, A., Lu, K. H., Smith, D. I., Kalli, K. R., Hartmann, L. C., et al. (2003) · PubMed · Cited by 92
Seo, J. H., Jeong, K. J., Oh, W. J., Sul, H. J., Sohn, J. S., Kim, Y. K., Cho, D. Y., Kang, J., Park, C. G., & Lee, H. Y. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.06.023 · Cited by 90
Prediction of resistance to chemotherapy in ovarian cancer: a systematic review
Lloyd, K. L., Cree, I. A., & Savage, R. S. (2015) · BMC Cancer · doi:10.1186/s12885-015-1101-8 · Cited by 87
Isobe, A., Sawada, K., Kinose, Y., Ohyagi-Hara, C., Nakatsuka, E., Makino, H., Ogura, T., Mizuno, T., Suzuki, N., Morii, E., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118080 · Cited by 87
Senescent Peritoneal Mesothelial Cells Promote Ovarian Cancer Cell Adhesion
Książek, K., Mikuła‐Pietrasik, J., Korybalska, K., Dworacki, G., Jörres, A., & Witowski, J. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080613 · Cited by 85
S1P stimulates chemotactic migration and invasion in OVCAR3 ovarian cancer cells
Park, K. S., Kim, M.-K., Lee, H. Y., Kim, S. D., Lee, S. Y., Kim, J. M., Ryu, S. H., & Bae, Y. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.02.112 · Cited by 82
Gaetano, C. G., Samadi, N., Tomsig, J. L., Macdonald, T. L., Lynch, K. R., & Brindley, D. N. (2009) · Molecular Carcinogenesis · doi:10.1002/mc.20524 · Cited by 80
Smith, A. M., Qualls, J. E., O’Brien, K., Balouzian, L., Johnson, P. F., Schultz‐Cherry, S., Smale, S. T., & Murray, P. J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.249235 · Cited by 78
Innate immune regulation by STAT ‐mediated transcriptional mechanisms
Li, H. S., & Watowich, S. S. (2014) · Immunological Reviews · doi:10.1111/imr.12198 · Cited by 77
Chang, D.-K., Peterson, E., Sun, J., Goudie, C., Drapkin, R., Liu, J. F., Matulonis, U. A., Zhu, Q. K., & Marasco, W. A. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1090075 · Cited by 77
Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells
Vidot, S., Witham, J., Agarwal, R., Greenhough, S., Bamrah, H. S., Tigyi, G., Kaye, S. B., & Richardson, A. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.01.017 · Cited by 75
Heath, R. M., Jayne, D. G., O’Leary, R., Morrison, E. E., & Guillou, P. J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601635 · Cited by 74
Kim, E., Park, J., Lim, S., Choi, J. W., Kim, H. S., Seok, H., Seo, J. K., Oh, K., Lee, D., Kim, K., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.209908 · Cited by 73
Fritsche, K. L., Byrge, M., & Feng, C. (1999) · Immunology Letters · doi:10.1016/s0165-2478(98)00109-6 · Cited by 73
Allavena, P., Peccatori, F. A., Maggioni, D., Erroi, A., Sironi, M., Colombo, N., Lissoni, A. A., Galazka, A. R., Meiers, W., & Mangioni, C. (1990) · PubMed · Cited by 73
Regulation of Ovarian Cancer Stem Cells or Tumor-Initiating Cells
Kwon, M. J., & Shin, Y. K. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14046624 · Cited by 72
Komdeur, F. L., Wouters, M. C. A., Workel, H. H., Tijans, A. M., Terwindt, A. L. J., Brunekreeft, K. L., Plat, A., Klip, H. G., Eggink, F. A., Leffers, N., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12077 · Cited by 72
Wang, F.-Q., So, J., Reierstad, S., & Fishman, D. A. (2005) · International Journal of Cancer · doi:10.1002/ijc.21421 · Cited by 71
B7-H6 expression correlates with cancer progression and patient's survival in human ovarian cancer.
Zhou, Y., Xu, Y., Chen, L., Xu, B., Wu, C., & Jiang, J. (2015) · PubMed Central · Cited by 71
Lysophosphatidic acid receptors in cancer pathobiology.
Tsujiuchi, T., Araki, M., Hirane, M., Dong, Y., & Fukushima, N. (2014) · PubMed · doi:10.14670/hh-29.313 · Cited by 70
Protein Kinases C Translocation Responses to Low Concentrations of Arachidonic Acid
O’Flaherty, J. T., Chadwell, B. A., Kearns, M. W., Sergeant, S., & Daniel, L. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101093200 · Cited by 64
Marth, C., Windbichler, G. H., Hausmaninger, H., Petru, E., Estermann, K., Pelzer, A. E., & Mueller‐Holzner, E. (2006) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2006.00622.x · Cited by 63
Burkhalter, R. J., Westfall, S. D., Liu, Y., & Stack, M. S. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.641092 · Cited by 63
The peritoneal tumour microenvironment of high‐grade serous ovarian cancer
Leinster, D. A., Kulbe, H., Everitt, G. L. A., Thompson, R. D., Perretti, M., Gavins, F. N. E., Cooper, D., Gould, D., Ennis, D. P., Lockley, M., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4002 · Cited by 62
Microenvironmental Regulation of Chemokine (C-X-C-Motif) Receptor 4 in Ovarian Carcinoma
Barbolina, M. V., Kim, M., Liu, Y., Shepard, J. A., Belmadani, A. A., Miller, R. J., Shea, L. D., & Stack, M. S. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0463 · Cited by 62
Guo, R., Qiao, Y., Zhou, Y., Li, L., Shi, H., & Chen, K. (2008) · Pathology International · doi:10.1111/j.1440-1827.2008.02306.x · Cited by 61
Ffrench, B., Gasch, C., O’Leary, J. J., & Gallagher, M. F. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-262 · Cited by 61
Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer
Mahdian-shakib, A., Dorostkar, R., Tat, M., Hashemzadeh, M. S., & Saidi, N. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.09.087 · Cited by 61
NF‐κB and chromatin: ten years on the path from basic mechanisms to candidate drugs
Natoli, G. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01103.x · Cited by 60
Song, Y., Wu, J., Oyesanya, R. A., Lee, Z., Mukherjee, A., & Fang, X. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1945 · Cited by 60
Steinkamp, M. P., Winner, K. K., Davies, S., Muller, C. Y., Zhang, Y., Hoffman, R. M., Shirinifard, A., Moses, M. E., Jiang, Y., & Wilson, B. S. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00097 · Cited by 56
Cytokine gene expression signature in ovarian clear cell carcinoma
Yanaihara, N., Anglesio, M. S., Ochiai, K., Hirata, Y., Saito, M., Nagata, C., Iida, Y., Takakura, S., Yamada, K., Tanaka, T., et al. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1533 · Cited by 55
Horiuchi, A., Imai, T., 清水, 元., Oka, K., Wang, C., Nikaido, T., & Konishi, I. (2003) · PubMed · Cited by 54
Lysophosphatidic acid induces cell migration through the selective activation of Akt1
Kim, E. K., Yun, S. J., Do, K. H., Kim, M. S., Cho, M., Suh, D., Kim, C. D., Kim, J. H., Birnbaum, M. J., & Bae, S. S. (2008) · Experimental & Molecular Medicine · doi:10.3858/emm.2008.40.4.445 · Cited by 47
Simpson-Abelson, M. R., Loyall, J. L., Lehman, H. K., Barnas, J. L., Minderman, H., O’Loughlin, K. L., Wallace, P. K., George, T. C., Peng, P., Kelleher, R. J., et al. (2013) · Europe PMC (PubMed Central) · Cited by 47
Hermans, C., Anz, D., Engel, J., Kirchner, T., Endres, S., & Mayr, D. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111757 · Cited by 45
Role of ether-linked lysophosphatidic acids in ovarian cancer cells
Lü, J., Xiao, Y.-J., Baudhuin, L. M., Hong, G., & Xu, Y. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30153-x · Cited by 41
Interleukin-12 Immunomodulation Delays the Onset of Lethal Peritoneal Disease of Ovarian Cancer
Cohen, C. A., Shea, A. A., Heffron, C. L., Schmelz, E. M., & Roberts, P. C. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2015.0049 · Cited by 40
Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancer
White, K. L., Rider, D. N., Kalli, K. R., Knutson, K. L., Jarvik, G. P., & Goode, E. L. (2011) · Cancer Causes & Control · doi:10.1007/s10552-011-9745-4 · Cited by 40
Recent insights into the role of NF-kappaB in ovarian carcinogenesis
Alvero, A. B. (2010) · Genome Medicine · doi:10.1186/gm177 · Cited by 36
Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives
Colombo, N., Conte, P., Pignata, S., Raspagliesi, F., & Scambia, G. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.017 · Cited by 30
Suppression of the p53-Dependent Replicative Senescence Response by Lysophosphatidic Acid Signaling
Kortlever, R. M., Brummelkamp, T. R., van Meeteren, L. A., Moolenaar, W. H., & Bernards, R. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0066 · Cited by 27
Nakayama, J., Raines, T. A., Lynch, K. R., & Slack‐Davis, J. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120071 · Cited by 23
Wu, J., Mukherjee, A., Lebman, D. A., & Fang, X. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0340 · Cited by 17
Expression Compilation of Several Putative Cancer Stem Cell Markers by Primary Ovarian Carcinoma
Jiabo, D., Refika, Y., Carl, G., Tjitske, D.-D. B., Leon, M., & Torensma, R. (2010) · Journal of Cancer Therapy · doi:10.4236/jct.2010.14026 · Cited by 9
Cited by
The Role of Tumor-Associated Macrophages in the Progression and Chemoresistance of Ovarian Cancer
Nowak, M., & Klink, M. (2020) · Cells · doi:10.3390/cells9051299 · Cited by 287
Motohara, T., Masuda, K., Morotti, M., Zheng, Y., El-Sahhar, S., Chong, K. Y., Wietek, N., Alsaadi, A., Carrami, E. M., Hu, Z., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0637-x · Cited by 218
Finkernagel, F., Reinartz, S., Schuldner, M., Malz, A., Jansen, J. M., Wagner, U., Worzfeld, T., Graumann, J., von Strandmann, E. P., & Müller, R. (2019) · Theranostics · doi:10.7150/thno.37549 · Cited by 55
Self-citation
Metadata
- Authors
- Worzfeld, T., Pogge von Strandmann, E., Huber, M., Adhikary, T., Wagner, U., Reinartz, S., & Müller, R.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2017-02-22
- Volume
- 7
- Pages
- 24-24
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2589658059
- Cited by
- 288
- References
- 262
- FWCI
- 26.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.